64Cu-SAR-bisPSMA
1 product
4 abstracts
1 target
Abstract
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.Org: Mayo Clinic Rochester, Rochester, MN, Clarity Pharmaceuticals, XCancer Omaha, Omaha, NE, Washington University in St. Louis, Mayo Clinic,
Abstract
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.Org: XCancer Omaha, Urology San Antonio, Tower Urology, New Mexico Cancer Center, Carolina Urologic Research Center and Atlantic Urology Clinics,
Abstract
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study).Org: Atlantic Urology Clinics,
Abstract
64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.Org: Clarity Pharmaceuticals, Eveleigh, Nepean Hospital, GenesisCare, Fort Myers, FL, Department of Theranostics and Nuclear Medicine,
Product
64Cu-SAR-bisPSMA